Stock IDIA IDORSIA LTD
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Idorsia Ltd

Equities

IDIA

CH0363463438

Market Closed - Swiss Exchange
Other stock markets
 16:31:59 30/04/2024 BST 		5-day change 1st Jan Change
1.81 CHF -2.95% Intraday chart for Idorsia Ltd -9.50% -14.38%
04-26 Idorsia Gets EU Medicines Regulator's Positive Opinion for Resistant Hypertension Treatment MT
04-11 Swiss Market Index Falls as ECB Signals June Rate Cut MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
GL
JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
GL
Idorsia publishes an invitation to a bondholder meeting
GL
Idorsia : On April 17, 2024, Idorsia published an Unaudited Financial Status as of March 31, 2024, in connection with an upcoming bondholder meeting. Unaudited Financial Status
PU
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
GL
Idorsia takes steps to address short-term liquidity needs
GL
Idorsia thanks Guy Braunstein for his years of service as he retires
GL
US FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
GL
Idorsia and Viatris successfully close the transaction for the global research and development collaboration
GL
Idorsia and Viatris enter into a significant global research and development collaboration
GL
Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration
PR
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
GL
New Phase 3 data with aprocitentan for patients with resistant hypertension has been presented at the American Society of Nephrology Kidney Week 2023
GL
Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
GL
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
GL
Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call
GL
Idorsia reacquires the world-wide rights to aprocitentan
GL
Tausif Butt to Join Idorsia Pharmaceuticals U.S. as President and General Manager
AQ
Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value
GL
Idorsia announces a cost reduction initiative to be implemented by the end of 2023
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. IDIA Stock
  4. News Idorsia Ltd
  5. Press Releases